Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clear cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    447 result(s) found for: Clear cell. Displaying page 1 of 23.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000473-23 Sponsor Protocol Number: RETRY Start Date*: 2012-05-29
    Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica
    Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER
    Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009251 Clear cell carcinoma of the kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001337-13 Sponsor Protocol Number: CRAD001LIC34T Start Date*: 2012-08-17
    Sponsor Name:APRO
    Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront rotations between sunitinib and everolimus versus sequential treatment of first line sunitinib and second line everoli...
    Medical condition: Metastatic clear cell renal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038416 Renal clear cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000127-32 Sponsor Protocol Number: ROPETAR Start Date*: 2011-11-03
    Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie
    Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin...
    Medical condition: Advanced or metastatic clear cell renal cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038416 Renal clear cell carcinoma LLT
    16.1 100000004864 10009251 Clear cell carcinoma of the kidney LLT
    16.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004011-12 Sponsor Protocol Number: SOGUG-2016-A-IEC(REN)-10 Start Date*: 2017-03-29
    Sponsor Name:SOGUG (Spanish Oncology Genitourinary Group)
    Full Title: Phase II study to evaluate efficacy and safety of sunitinib therapy in patients with metastatic renal clear cell carcinoma who have progressed to first-line immunotherapy treatment (INMUNOSUN Study)
    Medical condition: metastatic renal clear cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10038416 Renal clear cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004699-38 Sponsor Protocol Number: RCCC10 Start Date*: Information not available in EudraCT
    Sponsor Name:Klinikum der Universität Regensburg
    Full Title: A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma
    Medical condition: To investigate the effect of an anti-inflammatory therapy consisting of pioglitazone (Actos) in combination with an angiostatic treatment with sorafenib (Nexavar) and Interferin-Alpha (Roferon) on ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038416 Renal clear cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019726-14 Sponsor Protocol Number: CRO-2010-01 Start Date*: 2010-09-20
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
    Full Title: SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB.
    Medical condition: PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AGED >/= 65 YRS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038416 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003054-28 Sponsor Protocol Number: P070104 Start Date*: 2007-10-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude des marqueurs biologiques, histologiques et d’imagerie dans le traitement de 1ère ligne du carcinome à cellules claires du rein en situation métastatique par Sunitinib avant et après néphrec...
    Medical condition: Carcinome à cellules claires du rein en situation métastatique.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009251 carcinome à cellules claires du rein métastasé PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000589-47 Sponsor Protocol Number: 3475-427 Start Date*: 2016-09-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)
    Medical condition: Renal cell carcinoma (clear cell & non-clear cell), or kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001211-31 Sponsor Protocol Number: RG_10-177 Start Date*: 2012-02-24
    Sponsor Name:University of Birmingham
    Full Title: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02)
    Medical condition: Clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038416 Renal clear cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002109-73 Sponsor Protocol Number: NiCCC2013 Start Date*: 2013-11-14
    Sponsor Name:Greater Glasgow Health Board
    Full Title: A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium
    Medical condition: Recurrent clear cell carcinoma of the ovary or endometrium
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009252 Clear cell endometrial carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011669-10 Sponsor Protocol Number: ARQ 197-204 Start Date*: 2009-09-18
    Sponsor Name:ArQule, Inc.
    Full Title: A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors
    Medical condition: Microphthalmia Transcription Factor Associated Tumors: Clear cell sarcoma Alveolar soft part sarcoma Translocation associated renal cell carcinoma (Renal cell ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065865 Clear cell sarcoma LLT
    9.1 10001882 Alveolar soft part sarcoma LLT
    12.0 10067946 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000353-38 Sponsor Protocol Number: WX-2003-07-HR Start Date*: 2004-12-20
    Sponsor Name:Wilex AG
    Full Title: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence
    Medical condition: Renal cell carcinoma of the clear cell type after nephrectomy and no evidence of residual disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) GB (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003870-16 Sponsor Protocol Number: AlloTor Start Date*: 2008-09-22
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENA...
    Medical condition: PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENAL CELL CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005182-31 Sponsor Protocol Number: RCCSCAN Start Date*: 2017-02-23
    Sponsor Name:Lund University
    Full Title: "An exploratory study regarding the use of the biomarker DAT for image diagnosis of clear cell renal cell carcinoma"
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005132-26 Sponsor Protocol Number: CA209-025 Start Date*: 2012-09-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther...
    Medical condition: Advanced or metastatic (medically or surgically unresectable) clear-cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) HU (Completed) CZ (Completed) DK (Completed) ES (Completed) NO (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000706-12 Sponsor Protocol Number: SUNNIFORECAST Start Date*: 2017-01-23
    Sponsor Name:Goethe University Frankfurt
    Full Title: A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell ...
    Medical condition: The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Standard of Care in patients with previously untreated and advanced non-clear c...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) NL (Ongoing) CZ (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-004548-35 Sponsor Protocol Number: 15081982 Start Date*: 2010-08-20
    Sponsor Name:Radboud university nijmegen medical centre
    Full Title: PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER
    Medical condition: Patients with metastatic clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006085-40 Sponsor Protocol Number: 2011-006085-40 Start Date*: 2012-12-17
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma.
    Medical condition: Metastatic clear cell renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000928-71 Sponsor Protocol Number: GOIRC02/2008-TWIST Start Date*: 2008-11-14
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: “TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008
    Medical condition: Patients with advanced non-clear Cell Renal Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    9.1 10038458 Renal granular cell carcinoma PT
    9.1 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002957-67 Sponsor Protocol Number: CA209-010 Start Date*: 2011-11-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic T...
    Medical condition: Advanced/Metastatic renal cell carcinoma with a clear cell component
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038410 Renal cell carcinoma recurrent PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 21:15:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA